In8Bio (INAB) Prepaid Assets (2020 - 2026)
In8Bio (INAB) posted Prepaid Assets of $721000.0 for Q1 2026, up 178.38% sequentially from $259000.0 in Q4 2025, and down 13.86% YoY from $837000.0 in Q1 2025.
In8Bio (INAB) Prepaid Assets (2020 - 2026) Analysis & Trends
In8Bio has reported Prepaid Assets for 7 years, with the latest figure at $721000.0 in Q1 2026.
- Quarterly Prepaid Assets fell 13.86% year-over-year to $721000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $721000.0 (down 13.86% YoY) and the FY2025 annual result came in at $259000.0, down 42.44% from the prior year.
- Prepaid Assets advanced to $721000.0 in Q1 2026 per INAB's latest filing, from $259000.0 in the prior quarter.
- Over five years, Prepaid Assets peaked at $4.1 million in Q4 2022 and troughed at $145000.0 in Q2 2025.
- A 5-year average of $865411.8 and a median of $601000.0 in 2023 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2022 and 2023: Prepaid Assets soared 7692.31% in 2022, then slumped 86.95% in 2023.
- Over 5 years, Prepaid Assets stood at $4.1 million in 2022, then tumbled by 80.5% to $790000.0 in 2023, then plunged by 43.04% to $450000.0 in 2024, then sank by 42.44% to $259000.0 in 2025, then jumped by 178.38% to $721000.0 in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $721000.0, $259000.0, and $732000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 540,000.00 |
| Mar 31, 2026 | 721,000.00 |
| Dec 31, 2025 | 259,000.00 |
| Sep 30, 2025 | 732,000.00 |
| Jun 30, 2025 | 145,000.00 |
| Mar 31, 2025 | 837,000.00 |
| Dec 31, 2024 | 450,000.00 |
| Sep 30, 2024 | 177,000.00 |
| Jun 30, 2024 | 529,000.00 |
| Mar 31, 2024 | 449,000.00 |
| Dec 31, 2023 | 790,000.00 |
| Sep 30, 2023 | 262,000.00 |
| Jun 30, 2023 | 277,000.00 |
| Mar 31, 2023 | 601,000.00 |
| Dec 31, 2022 | 4.05 Mn |
| Sep 30, 2022 | 2.01 Mn |
| Jun 30, 2022 | 1.26 Mn |
| Mar 31, 2022 | 1.17 Mn |
| Dec 31, 2021 | 52,000.00 |
| Sep 30, 2021 | 3.20 Mn |